Extended Data Table 3.

List of animal cohorts used for this study. ED: Extended Data.

Cohort Name	No. Cohorts	Age	Sex	Background	Animal No.	Figures
adPPARδ vs adGFP	3	8–10 weeks	Male	C57BL/6J	4–6/genotype	Fig. 1a,b; Fig. 3c,d; Fig. 4a; ED. Fig 1a; ED. Fig 2f; ED. Fig. 3e
LACC1KD vs Scramble	2	8–10 weeks	Male	C57BL/6J	5/genotype	Fig. 1c–f; Fig. 3c,d; ED. Fig 3c–e
LPPARDKO vs wt, chow fed, metabolic phenotyping	2	8–10 and 32– 35 weeks	Male	C57BL/6J	6–8/genotype	ED. Fig. 2d–e
LPPARDKO vs wt, ad lib circadian study	4	8 weeks	Male /Female	C57BL/6J	3–5/genotype/time point	Fig. 2a,c–f; Fig. 3a–e; Fig. 4b; ED. Fig. 2a; ED. Fig. 3c–f
LPPARDKO vs wt, daytime restricted feeding	1	8 weeks	Male	C57BL/6J	3/genotype/time point	Fig. 2b; ED. Fig. 2c; ED. Fig. 3a,b,f; ED. Fig. 4a
LPPARDKO vs wt. GW501516 treatment	1	10–12 weeks	Male	C57BL/6J	4– 5/genotype/treatme nt	Fig. 3f; Fig. 4c; ED. Fig. 4b
wt, PC intra-peritoneal injection	1	10–12 weeks	Male	C57BL/6J	4/genotype/treatme nt	ED. Fig. 3h
wt, PC tall vein injection	2	8–10 weeks	Male	FVB/NJ	6/genotype/treatme nt	Fig. 3g
PPARα KO vs wt, lipid infusion	1	10–12 weeks	Male	C57BL/6J	6- 7/genotype/treatme nt	Fig. 3i; Fig. 4d–e
wt, db/db, PC (18:0/18:1) vs vehicle	1	8 weeks	Male	FVB/NJ	4–5/treatment	Fig. 4g–l; ED. Fig. 4h
wt, C57BL/5.1, Chow vs High Fat	1	32–35 weeks	Male	C57BL/6J	3–5/treatment/time point	ED. Fig. 4f–g